Does Lrig1 expression have a relationship with ERBB1 and ERBB2 expression in schizophrenia?
Abstract
Keywords
Schizophrenia , Lrig1 , ERBB1 , ERBB2 , EGFR
Kaynakça
- Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14:119-36.
- Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophr Bull. 2011;37:504-13.
- Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway K et al. The Leucine-rich repeat protein LRIG1 Is a negative regulator of ERBB family receptor tyrosine Kinases. J Biol Chem. 2004;279:47050-6.
- Alsina FC, Hita FJ, Fontanet PA, Irala D, Hedman H, Ledda F et al. Lrig1 is a cell‐intrinsic modulator of hippocampal dendrite complexity and
BDNF signaling. EMBO Rep. 2016;17:601-6. - Karabulut Uzunçakmak S, Şahin A, Tavaci Özçelik A, Halici Z. LRIG1 levels in chronic rhinosinusitis with nasal polyps. Cukurova Med J. 2023;48:323-9.
- Ji Y, Kumar R, Gokhale A, Chao H, Rycaj K, Chen X et al. LRIG1, a regulator of stem cell quiescence and a pleiotropic feedback tumor suppressor. Semin Cancer Biol. 2022;82:120-33.
- Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J et al. LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J. 2004;23:3270-81.
- Hita FJ, Bekinschtein P, Ledda F, Paratcha G. Leucine‐rich repeats and immunoglobulin‐like domains 1 deficiency affects hippocampal dendrite complexity and impairs cognitive function. Dev Neurobiol. 2021;81:774-85.
- Abe Y, Namba H, Zheng Y, Nawa H. In situ hybridization reveals developmental regulation of ERBB1-4 mRNA expression in mouse midbrain: implication of ERBB receptors for dopaminergic neurons. Neuroscience. 2009;161:95-110.
- Iwakura Y, Nawa H. ERBB1-4-dependent EGF/neuregulin signals and their cross talk in the central nervous system: pathological implications in schizophrenia and parkinson’s disease. Front Cell Neurosci. 2013;7:4.
